MRI Subtraction Maps for Tumor Progression Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to reliably differentiate between brain tumor progression and treatment effects, such as pseudoprogression and radiation necrosis, using conventional MRI, leading to challenges in patient management and treatment decisions.
Innovation Solution
The development of MRI subtraction maps, calculated by subtracting early post-contrast images from later images acquired at least 20 minutes after contrast administration, to distinguish between fast and slow contrast clearance populations, aiding in the differentiation between tumor progression and treatment effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional MRI is used to assess tumor response, then treatment monitoring can be performed, but reliable differentiation between tumor progression and treatment effects cannot be achieved
Solution Approach 1:
The patent segments the enhancing lesion into two distinct components: a blue component representing morphologically active tumor tissue and a red component representing non-tumoral tissue (necrosis, inflammation, edema). This segmentation is achieved through delayed contrast extravasation MRI acquired at least 20 minutes post-contrast administration, allowing differentiation of tissue types based on their distinct contrast kinetics. The segmentation resolves the technical contradiction by enabling precise identification of tumor progression (blue component increase) separate from treatment effects (red component increase).
Solution Approach 2:
The patent introduces a temporal dimension to conventional MRI by acquiring images at delayed time points (at least 20 minutes post-contrast administration). This temporal extension allows the system to capture the distinct contrast extravasation kinetics of tumor tissue versus non-tumoral tissue, creating a new dimension for tissue characterization. The delayed imaging dimension enables reliable differentiation between tumor progression and treatment effects, resolving the measurement precision limitation of conventional early imaging.
2Speed
If early post-contrast MRI images are used, then rapid assessment is possible, but high-resolution differentiation between tissue types cannot be achieved
Solution Approach 1:
The patent performs preliminary action by acquiring delayed contrast extravasation MRI images at least 20 minutes post-contrast administration before making treatment decisions. This preliminary delayed imaging allows the contrast agent to fully extravasate into different tissue compartments, establishing a baseline map of blue (tumor) and red (non-tumoral) components. This preliminary action ensures high measurement precision in tissue differentiation while maintaining clinical workflow efficiency.
Solution Approach 2:
The patent adds a temporal dimension to MRI assessment by acquiring images at delayed time points (at least 20 minutes post-contrast). This temporal dimension allows capture of the distinct contrast kinetics of different tissue types, enabling high-resolution differentiation between tumor and non-tumoral tissues. The delayed time dimension transforms the assessment from a single time-point evaluation to a kinetic profile analysis, resolving the precision-speed contradiction.
3Adaptability or versatility
If conventional MRI parameters are used, then standard treatment protocols can be followed, but accurate identification of viable tumor tissue cannot be achieved
Solution Approach 1:
The patent segments the enhancing lesion into blue component (morphologically active tumor) and red component (non-tumoral tissue). This segmentation provides accurate identification of viable tumor tissue while maintaining adaptability to standard treatment protocols. The blue component map can be overlaid on conventional MRI images, allowing integration with existing treatment planning systems and protocols while providing superior tissue characterization precision.
Solution Approach 2:
The patent creates a universal assessment tool that works across different treatment contexts (surgery, radiation, chemotherapy) and patient populations. The delayed contrast extravasation MRI technique and blue-red component segmentation provide a universal method for identifying viable tumor tissue regardless of the specific treatment protocol being used. This universal approach maintains adaptability to various standard protocols while achieving precise tumor identification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides high-resolution differentiation between tumor and non-tumoral tissues, enabling accurate assessment of tumor progression versus treatment effects, thereby improving patient management and treatment decisions.
Implementation Method 1
Delayed contrast extravasation MRI enables high resolution differentiation between tumoral regions from non tumoral regions
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
Apparatus for analyzing brain MRI, is disclosed. The apparatus comprises an input for receiving a first and a second MRI scans at the beginning and end of a predetermined time interval post contrast administration; a subtraction map former for forming a subtraction map from said first and said second MRI scans by analyzing said scans to distinguish between two primary populations, a slow population, in which contrast clearance from the tissue is slower than contrast accumulation, and a fast population in which clearance is faster than accumulation; and an output to provide an indication of distribution of said two primary populations, wherein said predetermined time period is at least twenty minutes.